Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 2/20 | 0.36 |
| ▸ | GABRD | O14764 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.36 |
| ▸ | GABRE | P78334 | 2/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17525660 | 1.00 | LMNA (0.43) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL18502988 | 1.00 | LMNA (0.43) | LMNATSHRMMP1MMP2MMP3 | |
| Hydrochloric Acid SCHEMBL18496191 | 0.98 | LMNA (0.42) | LMNATSHRMMP1MMP2MMP3 | |
| Hydrochloric Acid SCHEMBL18496190 | 0.98 | LMNA (0.42) | LMNATSHRMMP1MMP2MMP3 | |
| Hydrochloric Acid SCHEMBL28854944 | 0.98 | LMNA (0.42) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL18502990 | 0.81 | LMNA (0.41) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL23418403 | 0.79 | LMNA (0.44) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL6435735 | 0.79 | LMNA (0.39) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL6435729 | 0.79 | LMNA (0.39) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL19387301 | 0.79 | CYP19A1 (0.43) | LMNATSHRMMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603549-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | Yu, Ruey J., Dr. (US) | 2005-12-14 | — | — | EP | claimed |
| WO-2004082628-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-30 | — | — | WO | claimed |
| US-20250215465-A1 | ENANTIOSELECTIVE METHODS FOR PREPARING CHIRAL AMINE INTERMEDIATES | UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG (ZA) | 2025-07-03 | — | — | US | disclosed |
| EP-4493708-A1 | ENANTIOSELECTIVE METHODS FOR PREPARING CHIRAL AMINE INTERMEDIATES | University of the Witwatersrand, Johannesburg (ZA) | 2025-01-22 | — | — | EP | disclosed |
| CN-118974266-A | Enantioselective process for preparing chiral amine intermediates | 约翰内斯堡威特沃特斯兰德大学 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023197017-A1 | ENANTIOSELECTIVE METHODS FOR PREPARING CHIRAL AMINE INTERMEDIATES | UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG (ZA) | 2023-10-12 | — | — | WO | disclosed |
| US-9879036-B2 | Mitochondrial aldehyde dehydrogenase-2 binding compounds and methods of use thereof | AVIV THERAPEUTICS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170057982-A1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 BINDING COMPOUNDS AND METHODS OF USE THEREOF | AVIV THERAPEUTICS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| CN-1537000-B | Novel imidazolidine derivatives, their preparation and their use as VLA-4 antagonists | AVENTIS PHARMA GMBH | 2010-05-12 | — | — | CN | disclosed |
| EP-1603549-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | Yu, Ruey J., Dr. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040220264-A1 | Bioavailability and improved delivery of acidic pharmaceutical drugs | YU RUEY J | 2004-11-04 | — | — | US | disclosed |
| CN-1537000-A | Novel imidazolidine derivatives, their preparation and their use as VLA-4 antagonists | ������ҽҩ�¹�����˾ | 2004-10-13 | — | — | CN | disclosed |
| WO-2004082628-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057982-A1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 BINDING COMPOUNDS AND METHODS OF USE THEREOF | ALDH2, DLD, ALDH5A1 | LMNA 1722/4885TSHR 4472/4885MMP1 4645/4885 |
| US-20250215465-A1 | ENANTIOSELECTIVE METHODS FOR PREPARING CHIRAL AMINE INTERMEDIATES | BCAT1, BCAT2, CES1 | LMNA 1726/4885TSHR 1369/4885MMP1 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.